The results of two phase 3 trials investigating Survodutide, a weight loss drug from Boehringer Ingelheim, suggest that the ...

However, gastrointestinal adverse events -- primarily nausea, vomiting, diarrhea, and constipation -- occurred in 80.9-89.7% ...

Across 76 weeks in obesity/overweight without type 2 diabetes, survodutide achieved up to 16.6% mean weight loss versus 3.2% ...

Although medications with glucagon-like peptide-1 (GLP-1) receptor agonist activity have transformed the management of obesity and shown substantial cardiometabolic benefits, unmet needs remain.

GoodRx reports that GLP-1 medications, while not FDA-approved for high blood pressure, can aid in lowering it through weight ...

Until now, research into type 2 diabetes has focused primarily on insulin: if the body's cells become less responsive to the hormone produced in the pancreas, blood glucose levels rise over the long ...

The GLP-1 agonists weight loss drugs market offers growth potential through rising obesity rates, innovative drug approvals, and increased insurance coverage. Opportunities include expanding obesity ...

The US Food and Drug Administration has approved the first-ever generic glucagon injection kit for the treatment of severe hypoglycemia in patients with diabetes and as a diagnostic aid. The FDA ...